Oral delivery technologies experienced the largest growth in the quarter generating revenue of$274.9m, up 12.7 per cent, due according to Catalent to increased consumer demand for softgel and controlled-release products.
The firm’s clinical and development services business – which is soon to expanded with the acquisition of Aptuit’s assets - made the next biggest gains in the quarter with revenue increasing nearly 10 per cent to $47.6m.
These gains contrasted with Catalent’s sterile and packaging services units, which saw revenue fall 1.9 per cent to $52.7m and 12.1 per cent to $40.7m, respectively, as a result of a decline in customer demand and the fire that destroyed Catalent’s packaging facility in Corby in the UK earlier this year.
Despite this, Catalent’s net revenue for the three months ended September 30 was $410.5m up 7.8 per cent on the comparable period in fiscal 2011, while EBITDA from continuing operations increased by $27.6m to $70.5m.
More to follow...